MASLD in Diabetes and Obesity: Clinical Insights and Evidence-Based Management

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is increasingly recognized as a leading cause of chronic liver disease, particularly among individuals with diabetes and obesity. This review synthesizes recent evidence, explores the pathophysiological mechanisms linking MASLD with metabolic disorders, and discusses clinical features, diagnosis, management, and emerging therapies. Practical guidance is provided for clinicians to optimize care in this high-risk population.

Introduction

MASLD encompasses a spectrum of liver conditions characterized by excess hepatic fat accumulation, not attributable to significant alcohol consumption or other secondary causes. With the global rise in obesity and diabetes, MASLD prevalence has escalated, posing significant public health and clinical challenges. The bidirectional relationship with metabolic syndrome necessitates a nuanced, interdisciplinary approach to screening, diagnosis, and management. This article provides an evidence-based overview tailored for healthcare professionals, integrating recent advances and guideline updates.

Epidemiology / Disease Burden

MASLD affects an estimated 25-30% of the global population, with even higher prevalence among those with obesity and type 2 diabetes mellitus (T2DM). Up to 70% of individuals with T2DM and over 80% of those with obesity exhibit MASLD, underscoring its clinical relevance. The disease burden extends beyond hepatic morbidity, encompassing increased risk of cardiovascular disease, chronic kidney disease, and hepatocellular carcinoma. MASLD is now the leading indication for liver transplantation in many regions, reflecting its profound impact on health systems and patient outcomes.

Pathophysiology

MASLD pathogenesis is multifactorial, rooted in systemic metabolic dysfunction. Insulin resistance, a hallmark of both obesity and diabetes, drives excess free fatty acid delivery to hepatocytes and promotes de novo lipogenesis. Adipose tissue dysfunction, chronic inflammation, altered gut microbiota, and genetic predispositions further contribute. Hepatocellular lipid accumulation induces oxidative stress, mitochondrial dysfunction, and inflammatory signaling, progressing from simple steatosis to steatohepatitis and fibrosis. The interplay between endocrine, immune, and metabolic pathways highlights the systemic nature of MASLD in these populations.

Risk Factors

Key risk factors for MASLD include central obesity, T2DM, dyslipidemia, hypertension, and sedentary lifestyle. Genetic variants such as PNPLA3 and TM6SF2, older age, male sex, and certain ethnicities (e.g., Hispanic) increase susceptibility. In patients with diabetes, poor glycemic control and longer disease duration exacerbate risk. Overlap with other components of metabolic syndrome is common, and the aggregation of risk factors accelerates disease progression and complications.

Clinical Features

MASLD is often clinically silent, particularly in early stages. When symptomatic, patients may report right upper quadrant discomfort, fatigue, or nonspecific malaise. Hepatomegaly may be present on examination. Advanced disease manifests with features of liver dysfunction, portal hypertension, or cirrhosis. Importantly, in diabetes and obesity, MASLD is frequently discovered incidentally via abnormal liver enzymes or imaging. Vigilance is warranted, as progression to nonalcoholic steatohepatitis (NASH) or advanced fibrosis can occur insidiously.

Diagnosis

Diagnosis of MASLD requires evidence of hepatic steatosis via imaging (ultrasound, CT, MRI) or histology, exclusion of secondary causes, and assessment of alcohol intake. Noninvasive fibrosis assessment tools, such as transient elastography (FibroScan) and serum biomarkers (FIB-4, NAFLD fibrosis score), are recommended for risk stratification. In diabetics and those with obesity, routine screening is advocated due to high prevalence and risk of progression. Liver biopsy remains the gold standard for definitive diagnosis and staging when noninvasive data are inconclusive or advanced disease is suspected.

Treatment & Management

Lifestyle modification is the cornerstone of MASLD management, emphasizing weight reduction (≥7-10%), dietary optimization, and physical activity. In patients with diabetes, optimal glycemic and lipid control are essential. Pharmacotherapy may be considered for those with biopsy-proven NASH or significant fibrosis, particularly when lifestyle measures are insufficient. Pioglitazone and GLP-1 receptor agonists demonstrate benefit in selected patients, while vitamin E may be considered in non-diabetic NASH. Bariatric surgery offers substantial benefits for eligible obese patients with advanced disease.

Recent Advances / Emerging Therapies

Recent advances include novel agents targeting metabolic, inflammatory, and fibrotic pathways. Semaglutide, a GLP-1 agonist, and SGLT2 inhibitors have shown promise in improving liver histology and metabolic parameters. FXR agonists (obeticholic acid), PPAR agonists, and FGF21 analogues are under investigation, with encouraging early-phase results. Noninvasive diagnostic biomarkers and imaging modalities are also evolving, enabling earlier detection and personalized risk assessment.

Guideline Recommendations

Major societies, including AASLD, EASL, and ADA, recommend routine MASLD screening in high-risk groups (diabetes, obesity, metabolic syndrome). Multidisciplinary management is endorsed, integrating hepatology, endocrinology, and primary care. Risk stratification using noninvasive tools, lifestyle intervention, and individualized pharmacotherapy are key pillars. Surveillance for hepatocellular carcinoma and cardiovascular risk reduction are integral components of comprehensive care.

Conclusion

MASLD represents a significant clinical challenge in the context of diabetes and obesity, driven by shared metabolic and pathophysiological mechanisms. Timely identification, targeted intervention, and adherence to guideline-based management can mitigate progression and improve outcomes. Ongoing research into novel therapies and diagnostic modalities holds promise for more effective, individualized care strategies for at-risk populations.